George Coukos

List of Publications by Year
in descending order

311 papers	44,284 citations	3933 88 h-index	2385 198 g-index
335 all docs	335 docs citations	335 times ranked	50220 citing authors

#	Article	IF	Citations
1	Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine, 2004, 10, 942-949.	30.7	4,442
2	Cancer immunotherapy comes of age. Nature, 2011, 480, 480-489.	27.8	3,115
3	Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer. New England Journal of Medicine, 2003, 348, 203-213.	27.0	2,930
4	Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews Cancer, 2011, 11, 719-725.	28.4	1,084
5	Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. Nature, 2011, 475, 226-230.	27.8	1,071
6	microRNAs exhibit high frequency genomic alterations in human cancer. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9136-9141.	7.1	977
7	The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nature Cell Biology, 2008, 10, 202-210.	10.3	924
8	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nature Reviews Cancer, 2015, 15, 668-679.	28.4	839
9	Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nature Medicine, 2014, 20, 607-615.	30.7	742
10	Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood, 2009, 114, 1141-1149.	1.4	688
11	T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis. Cancer Research, 2012, 72, 2162-2171.	0.9	663
12	Laser-capture microdissection. Nature Protocols, 2006, 1, 586-603.	12.0	651
13	Modulation of the antitumor immune response by complement. Nature Immunology, 2008, 9, 1225-1235.	14.5	612
14	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
15	Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors. Cancer Research, 2013, 73, 3591-3603.	0.9	604
16	Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. Cancer Cell, 2015, 28, 529-540.	16.8	601
17	Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis. Gynecologic Oncology, 2012, 124, 192-198.	1.4	527
18	Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nature Reviews Cancer, 2017, 17, 254-268.	28.4	527

#	Article	IF	Citations
19	Deciphering and Reversing Tumor Immune Suppression. Immunity, 2013, 39, 61-73.	14.3	496
20	Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 7004-7009.	7.1	491
21	Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nature Medicine, 2008, 14, 28-36.	30.7	481
22	Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. Cancer Cell, 2019, 35, 885-900.e10.	16.8	475
23	Tumor-infiltrating dendritic cell precursors recruited by a Î²-defensin contribute to vasculogenesis under the influence of Vegf-A. Nature Medicine, 2004, 10, 950-958.	30.7	431
24	Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis, 2018, 21, 425-532.	7.2	429
25	The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nature Reviews Immunology, 2011, 11, 702-711.	22.7	390
26	Distinct Expression Levels and Patterns of Stem Cell Marker, Aldehyde Dehydrogenase Isoform 1 (ALDH1), in Human Epithelial Cancers. PLoS ONE, 2010, 5, e10277.	2.5	362
27	T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy. Cancer Discovery, 2014, 4, 522-526.	9.4	357
28	Radiotherapy combination opportunities leveraging immunity for the next oncology practice. Ca-A Cancer Journal for Clinicians, 2017, 67, 65-85.	329.8	344
29	MicroRNA Microarray Identifies <i>Let-7i</i> as a Novel Biomarker and Therapeutic Target in Human Epithelial Ovarian Cancer. Cancer Research, 2008, 68, 10307-10314.	0.9	343
30	Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Science Translational Medicine, 2018, 10, .	12.4	326
31	miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biology and Therapy, 2008, 7, 255-264.	3.4	324
32	Relationship between B7-H4, Regulatory T Cells, and Patient Outcome in Human Ovarian Carcinoma. Cancer Research, 2007, 67, 8900-8905.	0.9	294
33	Mechanisms of microRNA deregulation in human cancer. Cell Cycle, 2008, 7, 2643-2646.	2.6	293
34	Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function. Frontiers in Immunology, 2019, 10, 925.	4.8	288
35	<i>In Vivo</i> Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB). Cancer Research, 2011, 71, 4617-4627.	0.9	256
36	Therapeutic PD-1 Pathway Blockade Augments with Other Modalities of Immunotherapy T-Cell Function to Prevent Immune Decline in Ovarian Cancer. Cancer Research, 2013, 73, 6900-6912.	0.9	253

#	Article	IF	Citations
37	Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion. Nature Immunology, 2020, 21, 1540-1551.	14.5	252
38	Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity. PLoS Computational Biology, 2017, 13, e1005725.	3.2	250
39	Targeting HER-2/neu in Early Breast Cancer Development Using Dendritic Cells with Staged Interleukin-12 Burst Secretion. Cancer Research, 2007, 67, 1842-1852.	0.9	247
40	Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Modern Pathology, 2009, 22, 393-402.	5.5	241
41	CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor. Clinical Cancer Research, 2014, 20, 44-55.	7.0	241
42	Targeting the tumor vasculature to enhance T cell activity. Current Opinion in Immunology, 2015, 33, 55-63.	5.5	237
43	High-throughput automated organoid culture via stem-cell aggregation in microcavity arrays. Nature Biomedical Engineering, 2020, 4, 863-874.	22.5	231
44	T cell–induced CSF1 promotes melanoma resistance to PD1 blockade. Science Translational Medicine, 2018, 10, .	12.4	229
45	Signal pathway profiling of ovarian cancer from human tissue specimens using reverse–phase protein microarrays. Proteomics, 2003, 3, 2085-2090.	2.2	226
46	High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound InterferonÎ³-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome. Molecular and Cellular Proteomics, 2018, 17, 533-548.	3.8	224
47	Interpretation of T cell states from single-cell transcriptomics data using reference atlases. Nature Communications, 2021, 12, 2965.	12.8	210
48	Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes. Nature Biotechnology, 2019, 37, 1283-1286.	17.5	208
49	Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Research, 2003, 63, 3403-12.	0.9	204
50	Whole Tumor Antigen Vaccines: Where Are We?. Vaccines, 2015, 3, 344-372.	4.4	203
51	Whole tumor antigen vaccines. Seminars in Immunology, 2010, 22, 132-143.	5.6	201
52	Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes. Nature Communications, 2020, 11, 1293.	12.8	196
53	Vascular leukocytes contribute to tumor vascularization. Blood, 2005, 105, 679-681.	1.4	183
54	A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside. Clinical Cancer Research, 2013, 19, 4801-4815.	7.0	178

#	Article	IF	Citations
55	Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nature Communications, 2017, 8, 593.	12.8	175
56	Tumor Vascular Proteins As Biomarkers in Ovarian Cancer. Journal of Clinical Oncology, 2007, 25, 852-861.	1.6	172
57	KLF17 is a negative regulator of epithelialâ€"mesenchymal transition and metastasis in breast cancer. Nature Cell Biology, 2009, 11, 1297-1304.	10.3	172
58	Mass spectrometry-based antigen discovery for cancer immunotherapy. Current Opinion in Immunology, 2016, 41, 9-17.	5.5	165
59	Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. Cancer Discovery, 2022, 12, 108-133.	9.4	165
60	The Human Vaccines Project: A roadmap for cancer vaccine development. Science Translational Medicine, 2016, 8, 334ps9.	12.4	162
61	Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor. Molecular Therapy, 2012, 20, 633-643.	8.2	161
62	Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. Science Advances, 2021, 7, .	10.3	157
63	Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. OncoImmunology, 2013, 2, e22664.	4.6	154
64	Therapeutic MicroRNA Strategies in Human Cancer. AAPS Journal, 2009, 11, 747-57.	4.4	153
65	Double-Negative Feedback Loop between Reprogramming Factor LIN28 and microRNA *let-7* Regulates Aldehyde Dehydrogenase 1â€"Positive Cancer Stem Cells. Cancer Research, 2010, 70, 9463-9472.	0.9	150
66	The Length Distribution and Multiple Specificity of Naturally Presented HLA-I Ligands. Journal of Immunology, 2018, 201, 3705-3716.	0.8	145
67	Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Annals of Oncology, 2019, 30, 1902-1913.	1.2	144
68	The NAD-Booster Nicotinamide Riboside Potently Stimulates Hematopoiesis through Increased Mitochondrial Clearance. Cell Stem Cell, 2019, 24, 405-418.e7.	11.1	143
69	Identification of MicroRNAs Regulating Reprogramming Factor LIN28 in Embryonic Stem Cells and Cancer Cells. Journal of Biological Chemistry, 2010, 285, 41961-41971.	3.4	136
70	â€˜Hotspotsâ€™ of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization. Frontiers in Immunology, 2017, 8, 1367.	4.8	133
71	Generation of a Syngeneic Mouse Model to Study the Effects of Vascular Endothelial Growth Factor in Ovarian Carcinoma. American Journal of Pathology, 2002, 161, 2295-2309.	3.8	129
72	The ovarian cancer oncobiome. Oncotarget, 2017, 8, 36225-36245.	1.8	129

#	Article	IF	Citations
73	The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. , 2019, 7, 109.		129
74	Turning up the heat on non-immunoreactive tumours: opportunities for clinical development. Lancet Oncology, The, 2020, 21, e419-e430.	10.7	128
75	Involvement of Endothelial CD44 during in Vivo Angiogenesis. American Journal of Pathology, 2006, 169, 325-336.	3.8	123
76	Sensitive and frequent identification of high avidity neo-epitopeÂspecific CD8 + T cells in immunotherapy-naive ovarian cancer. Nature Communications, 2018, 9, 1092.	12.8	122
77	Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells. , 2019, 7, 257.		120
78	HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Molecular Therapy, 2005, 12, 789-802.	8.2	119
79	Integrative Genomic Analysis of Protein Kinase C (PKC) Family Identifies PKCÎ1 as a Biomarker and Potential Oncogene in Ovarian Carcinoma. Cancer Research, 2006, 66, 4627-4635.	0.9	118
80	Intraepithelial T cells and tumor proliferation. Cancer, 2009, 115, 2891-2902.	4.1	118
81	Immunotherapy for Ovarian Cancer: What's Next?. Journal of Clinical Oncology, 2011, 29, 925-933.	1.6	116
82	Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment. , 2019, 7, 309.		112
83	Integrative Genomic Analysis of Phosphatidylinositol 3â€²-Kinase Family Identifies PIK3R3 as a Potential Therapeutic Target in Epithelial Ovarian Cancer. Clinical Cancer Research, 2007, 13, 5314-5321.	7.0	111
84	Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology, Immunotherapy, 2012, 61, 629-641.	4.2	109
85	Estimating the Contribution of Proteasomal Spliced Peptides to the HLA-I Ligandome*. Molecular and Cellular Proteomics, 2018, 17, 2347-2357.	3.8	105
86	Genetic and Pharmacologic Inhibition of Complement Impairs Endothelial Cell Function and Ablates Ovarian Cancer Neovascularization. Neoplasia, 2012, 14, 994-IN1.	5.3	103
87	Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochemical and Biophysical Research Communications, 2003, 303, 1169-1178.	2.1	101
88	Neutrophils suppress tumorâ€infiltrating T cells in colon cancer via matrix metalloproteinaseâ€mediated activation of <scp>TGF</scp> Î². EMBO Molecular Medicine, 2020, 12, e10681.	6.9	100
89	A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy. Nature Biotechnology, 2020, 38, 426-432.	17.5	100
90	Endothelin B Receptor, a New Target in Cancer Immune Therapy. Clinical Cancer Research, 2009, 15, 4521-4528.	7.0	99

#	Article	IF	Citations
91	A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. Journal of Translational Medicine, 2012, 10, 157.	4.4	95
92	N-Cadherin-Mediated Human Granulosa Cell Adhesion Prevents Apoptosis. American Journal of Pathology, 1999, 154, 1391-1406.	3.8	93
93	Identification of tumor antigens with immunopeptidomics. Nature Biotechnology, 2022, 40, 175-188.	17.5	93
94	Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood–brain barrier divide. Expert Opinion on Drug Delivery, 2013, 10, 907-926.	5.0	92
95	Adjuvants for Enhancing the Immunogenicity of Whole Tumor Cell Vaccines. International Reviews of Immunology, 2011, 30, 150-182.	3.3	91
96	Tamoxifen loaded folic acid armed PEGylated magnetic nanoparticles for targeted imaging and therapy of cancer. Colloids and Surfaces B: Biointerfaces, 2013, 106, 117-125.	5.0	91
97	Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosomes and Cancer, 2011, 50, 606-618.	2.8	90
98	Rational combinations of immunotherapy with radiotherapy in ovarian cancer. Lancet Oncology, The, 2019, 20, e417-e433.	10.7	89
99	Phage antibody display libraries: a powerful antibody discovery platform for immunotherapy. Critical Reviews in Biotechnology, 2016, 36, 276-289.	9.0	88
100	MicroRNA epigenetic alterations in human cancer: One step forward in diagnosis and treatment. International Journal of Cancer, 2008, 122, 963-968.	5.1	84
101	T Cells Bearing a Chimeric Antigen Receptor against Prostate-Specific Membrane Antigen Mediate Vascular Disruption and Result in Tumor Regression. Cancer Immunology Research, 2015, 3, 68-84.	3.4	84
102	Oncolytic HSV Exerts Direct Antiangiogenic Activity in Ovarian Carcinoma. Human Gene Therapy, 2005, 16, 765-778.	2.7	81
103	T-cell repertoire analysis and metrics of diversity and clonality. Current Opinion in Biotechnology, 2020, 65, 284-295.	6.6	79
104	Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoediting. Cell Reports Medicine, 2021, 2, 100194.	6.5	77
105	Angiogenesis and the Tumor Vasculature as Antitumor Immune Modulators: The Role of Vascular Endothelial Growth Factor and Endothelin. Current Topics in Microbiology and Immunology, 2010, 344, 129-148.	1.1	76
106	Transcriptional coactivator Drosophila eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth. Cancer Research, 2005, 65, 925-32.	0.9	75
107	Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression. Journal of Experimental Medicine, 2021, 218, .	8.5	74
108	Immunotherapy in Ovarian Cancer: Are We There Yet?. Journal of Clinical Oncology, 2019, 37, 2460-2471.	1.6	73

#	Article	IF	Citations
109	A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinomaâ€"A Proof of Antigen Discovery Feasibility in Three Patients. Frontiers in Immunology, 2019, 10, 1832.	4.8	73
110	TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clinical Cancer Research, 2003, 9, 1517-27.	7.0	73
111	Human Immunodeficiency Virus Type 1 Causes Productive Infection of Macrophages in Primary Placental Cell Cultures. Journal of Infectious Diseases, 1994, 169, 746-753.	4.0	70
112	Labelâ€Free Optofluidic Nanobiosensor Enables Realâ€Time Analysis of Singleâ€Cell Cytokine Secretion. Small, 2018, 14, e1800698.	10.0	70
113	Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation. Cancer Biology and Therapy, 2008, 7, 1194-1205.	3.4	69
114	Differentiation-Dependent Expression of the BCL-2 Proto-Oncogene in the Human Trophoblast Lineage. Journal of the Society for Gynecologic Investigation, 1994, 1, 164-172.	1.7	66
115	Different Effects of Glucose Starvation on Expression and Stability of VEGF mRNA Isoforms in Murine Ovarian Cancer Cells. Biochemical and Biophysical Research Communications, 2002, 292, 860-868.	2.1	65
116	Replication-Selective Herpes Simplex Virus Type 1 Mutant Therapy of Cervical Cancer Is Enhanced by Low-Dose Radiation. Human Gene Therapy, 2002, 13, 627-639.	2.7	65
117	Cancer Cell Lines as Genetic Models of Their Parent Histology: Analyses Based on Array Comparative Genomic Hybridization. Cancer Research, 2007, 67, 3594-3600.	0.9	65
118	Whole tumor antigen vaccination using dendritic cells: Comparison of RNA electroporation and pulsing with UV-irradiated tumor cells. Journal of Translational Medicine, 2008, 6, 21.	4.4	65
119	Ovarian Carcinoma Expresses the NKG2D Ligand Letal and Promotes the Survival and Expansion of CD28â€" Antitumor T Cells. Cancer Research, 2004, 64, 2175-2182.	0.9	64
120	Myeloid antigen-presenting cell niches sustain antitumor TÂcells and license PD-1 blockade via CD28 costimulation. Cancer Cell, 2021, 39, 1623-1642.e20.	16.8	64
121	Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Cancer Gene Therapy, 2000, 7, 275-283.	4.6	63
122	Multifunctional mitoxantrone-conjugated magnetic nanosystem for targeted therapy of folate receptor-overexpressing malignant cells. Journal of Nanobiotechnology, 2015, 13, 26.	9.1	63
123	Neoantigen-based cancer immunotherapy. Annals of Translational Medicine, 2016, 4, 262-262.	1.7	63
124	TCR-engineered T cells to treat tumors: Seeing but not touching?. Seminars in Immunology, 2016, 28, 10-21.	5.6	62
125	18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1859-1868.	6.4	62
126	Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Donâ€™t Forget the Fuel. Frontiers in Immunology, 2017, 8, 267.	4.8	61

#	Article	IF	Citations
127	Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment. Cancer Biology and Therapy, 2006, 5, 635-642.	3.4	60
128	Primary Human Ovarian Epithelial Cancer Cells Broadly Express HER2 at Immunologically-Detectable Levels. PLoS ONE, 2012, 7, e49829.	2.5	60
129	Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. Cell Reports, 2021, 36, 109412.	6.4	60
130	Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. Frontiers in Bioscience - Landmark, 2009, Volume, 1761.	3.0	59
131	Tumor endothelial marker 1–specific DNA vaccination targets tumor vasculature. Journal of Clinical Investigation, 2014, 124, 1497-1511.	8.2	59
132	A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy. , 2018, 6, 156.		58
133	Immunotherapy opportunities in ovarian cancer. Expert Review of Anticancer Therapy, 2008, 8, 243-257.	2.4	57
134	A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. Journal of Translational Medicine, 2013, 11, 149.	4.4	57
135	Safety and Tolerability of Adoptive Cell Therapy in Cancer. Drug Safety, 2019, 42, 315-334.	3.2	57
136	Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. Journal of Translational Medicine, 2009, 7, 49.	4.4	56
137	Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk. OncoImmunology, 2016, 5, e1240857.	4.6	56
138	miRNAs in Human Cancer. Methods in Molecular Biology, 2012, 822, 295-306.	0.9	56
139	The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. Cancer Research, 2003, 63, 4225-31.	0.9	56
140	LETAL, A Tumor-Associated NKG2D Immunoreceptor Ligand, Induces Activation and Expansion of Effector Immune Cells. Cancer Biology and Therapy, 2003, 2, 446-451.	3.4	55
141	Specific targeting of cancer cells by multifunctional mitoxantrone-conjugated magnetic nanoparticles. Journal of Drug Targeting, 2013, 21, 328-340.	4.4	55
142	Cathepsin S Regulates Antigen Processing and T Cell Activity in Non-Hodgkin Lymphoma. Cancer Cell, 2020, 37, 674-689.e12.	16.8	55
143	A Combined Array-Based Comparative Genomic Hybridization and Functional Library Screening Approach Identifies mir-30d As an Oncomir in Cancer. Cancer Research, 2012, 72, 154-164.	0.9	53
144	Structural dissimilarity from self drives neoepitope escape from immune tolerance. Nature Chemical Biology, 2020, 16, 1269-1276.	8.0	53

#	Article	IF	Citations
145	Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes. Journal of Translational Medicine, 2011, 9, 131.	4.4	52
146	The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28–Costimulated T Cells Prepared for Adoptive Therapy. Clinical Cancer Research, 2015, 21, 2840-2850.	7.0	52
147	A Xenograft Mouse Model Coupled with In-depth Plasma Proteome Analysis Facilitates Identification of Novel Serum Biomarkers for Human Ovarian Cancer. Journal of Proteome Research, 2012, 11, 678-691.	3.7	51
148	miRNA genetic alterations in human cancers. Expert Opinion on Biological Therapy, 2007, 7, 1375-1386.	3.1	50
149	Chemotherapy resistance in ovarian cancer: New molecular perspectives. Obstetrics and Gynecology, 1998, 91, 783-792.	2.4	49
150	Sensitive Immunopeptidomics by Leveraging Available Large-Scale Multi-HLA Spectral Libraries, Data-Independent Acquisition, and MS/MS Prediction. Molecular and Cellular Proteomics, 2021, 20, 100080.	3.8	49
151	Distinct Effects of IL-18 on the Engraftment and Function of Human Effector CD8+ T Cells and Regulatory T Cells. PLoS ONE, 2008, 3, e3289.	2.5	48
152	Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer. International Journal of Nanomedicine, 2014, 9, 1855.	6.7	48
153	Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy. OncoImmunology, 2017, 6, e1326442.	4.6	48
154	The C-terminal extension landscape of naturally presented HLA-I ligands. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 5083-5088.	7.1	48
155	Tumor immune surveillance and ovarian cancer. Cancer and Metastasis Reviews, 2011, 30, 141-151.	5.9	47
156	Mass Spectrometry Based Immunopeptidomics Leads to Robust Predictions of Phosphorylated HLA Class I Ligands. Molecular and Cellular Proteomics, 2020, 19, 390-404.	3.8	47
157	Predicting time to ovarian carcinoma recurrence using protein markers. Journal of Clinical Investigation, 2013, 123, 3740-50.	8.2	46
158	A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". Journal of Translational Medicine, 2008, 6, 81.	4.4	45
159	Beyond CA125: the coming of age of ovarian cancer biomarkers. Biomarkers in Medicine, 2009, 3, 275-288.	1.4	44
160	Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform. Journal of Immunological Methods, 2011, 363, 221-232.	1.4	44
161	Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors—Response. Cancer Research, 2014, 74, 633-634.	0.9	44
162	Tumour-reactive T cell subsets in the microenvironment of ovarian cancer. British Journal of Cancer, 2019, 120, 424-434.	6.4	44

#	Article	IF	Citations
163	Regulated Expression and Potential Roles of p53 and Wilmsâ€™ Tumor Suppressor Gene (WT1) during Follicular Development in the Human Ovary1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 449-459.	3.6	43
164	Ultraconserved elements: Genomics, function and disease. RNA Biology, 2008, 5, 132-134.	3.1	43
165	In Vivo Dendritic Cell Tracking Using Fluorescence Lifetime Imaging and Near-Infrared-Emissive Polymersomes. Molecular Imaging and Biology, 2009, 11, 167-177.	2.6	43
166	Day-4 Myeloid Dendritic Cells Pulsed with Whole Tumor Lysate Are Highly Immunogenic and Elicit Potent Anti-Tumor Responses. PLoS ONE, 2011, 6, e28732.	2.5	43
167	Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate. Journal of Translational Medicine, 2011, 9, 198.	4.4	43
168	Chemoimmunotherapy Using Pegylated Liposomal Doxorubicin and Interleukin-18 in Recurrent Ovarian Cancer: A Phase I Dose-Escalation Study. Cancer Immunology Research, 2013, 1, 168-178.	3.4	43
169	Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma. Clinical Cancer Research, 2003, 9, 264-72.	7.0	43
170	TIE-2 expressing monocytes in human cancers. OncoImmunology, 2017, 6, e1303585.	4.6	42
171	A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma. Journal of Translational Medicine, 2019, 17, 391.	4.4	42
172	Mass spectrometryâ€"driven exploration reveals nuances of neoepitope-driven tumor rejection. JCI Insight, 2019, 4, .	5.0	42
173	Personalized approaches to active immunotherapy in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 72-82.	7.4	41
174	Transcriptional Regulation of PIK3CA Oncogene by NF-ÎºB in Ovarian Cancer Microenvironment. PLoS ONE, 2008, 3, e1758.	2.5	41
175	Sensitive identification of neoantigens and cognate TCRs in human solid tumors. Nature Biotechnology, 2022, 40, 656-660.	17.5	41
176	Clinical predictors of bevacizumab-associated gastrointestinal perforation. Gynecologic Oncology, 2011, 120, 464-469.	1.4	40
177	A severe case of neuro-SjÃ¶grenâ€™s syndrome induced by pembrolizumab. , 2018, 6, 110.		40
178	Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy. Journal of Translational Medicine, 2011, 9, 77.	4.4	38
179	Ovarian Cancer Early Detection Claims Are Biased. Clinical Cancer Research, 2008, 14, 7574.1-7574.	7.0	37
180	TIE-2-expressing monocytes are lymphangiogenic and associate specifically with lymphatics of human breast cancer. OncoImmunology, 2016, 5, e1073882.	4.6	37

#	Article	IF	Citations
181	A New Twist on Radiation Oncology: Low-Dose Irradiation Elicits Immunostimulatory Macrophages that Unlock Barriers to Tumor Immunotherapy. Cancer Cell, 2013, 24, 559-561.	16.8	36
182	Label-free identification of activated T lymphocytes through tridimensional microsensors on chip. Biosensors and Bioelectronics, 2017, 94, 193-199.	10.1	36
183	Integrated Analysis of Multiple Microarray Datasets Identifies a Reproducible Survival Predictor in Ovarian Cancer. PLoS ONE, 2011, 6, e18202.	2.5	35
184	1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2). Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4330-4333.	2.2	35
185	The emergence of immunomodulation: Combinatorial immunochemotherapy opportunities for the next decade. Gynecologic Oncology, 2010, 116, 222-233.	1.4	33
186	Novel surface targets and serum biomarkers from the ovarian cancer vasculature. Cancer Biology and Therapy, 2011, 12, 169-180.	3.4	33
187	All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy. Current Opinion in Biotechnology, 2020, 65, 75-87.	6.6	33
188	Involvement of Placental Neurohormones in Human Parturition. Annals of the New York Academy of Sciences, 1991, 622, 331-340.	3.8	32
189	MicroRNAs: A New Insight into Cancer Genome. Cell Cycle, 2006, 5, 2216-2219.	2.6	32
190	Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18. Journal of Translational Medicine, 2009, 7, 104.	4.4	32
191	TIE-2 and VEGFR Kinase Activities Drive Immunosuppressive Function of TIE-2–Expressing Monocytes in Human Breast Tumors. Clinical Cancer Research, 2013, 19, 3439-3449.	7.0	32
192	Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal. Frontiers in Immunology, 2020, 11, 1215.	4.8	32
193	Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer. European Journal of Cancer, 2020, 135, 173-182.	2.8	32
194	Immunotherapy for gynaecological malignancies. Expert Opinion on Biological Therapy, 2005, 5, 1193-1210.	3.1	31
195	Doppler Velocimetry in Prolonged Pregnancy. Obstetrics and Gynecology, 1991, 77, 213-216.	2.4	30
196	Expression of Activated PIK3CA in Ovarian Surface Epithelium Results in Hyperplasia but Not Tumor Formation. PLoS ONE, 2009, 4, e4295.	2.5	30
197	Potential approaches for more successful dendritic cell-based immunotherapy. Expert Opinion on Biological Therapy, 2015, 15, 569-582.	3.1	30
198	Interferon β adenoviral gene therapy in a patient with ovarian cancer. Nature Clinical Practice Oncology, 2006, 3, 633-639.	4.3	29

#	Article	IF	Citations
199	High-Throughput Biomarker Segmentation on Ovarian Cancer Tissue Microarrays via Hierarchical Normalized Cuts. IEEE Transactions on Biomedical Engineering, 2012, 59, 1240-1252.	4.2	29
200	CHEMOTHERAPY RESISTANCE IN OVARIAN CANCER. Obstetrics and Gynecology, 1998, 91, 783-792.	2.4	28
201	Development of 124I Immuno-PET Targeting Tumor Vascular TEM1/Endosialin. Journal of Nuclear Medicine, 2014, 55, 500-507.	5.0	28
202	In silico and cell-based analyses reveal strong divergence between prediction and observation of T-cellâ€"recognized tumor antigen T-cell epitopes. Journal of Biological Chemistry, 2017, 292, 11840-11849.	3.4	28
203	50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial. International Journal of Radiation Oncology Biology Physics, 2019, 103, 320-334.	0.8	28
204	Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy. Clinical Cancer Research, 2017, 23, 1955-1966.	7.0	27
205	Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer. Npj Vaccines, 2021, 6, 36.	6.0	27
206	Prolonged Remission of Recurrent, Metastatic Placental Site Trophoblastic Tumor after Chemotherapy. Gynecologic Oncology, 2000, 76, 115-117.	1.4	26
207	Lighting up the tumor fire with low-dose irradiation. Trends in Immunology, 2022, 43, 173-179.	6.8	26
208	Immune Therapy Opportunities in Ovarian Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e228-e240.	3.8	25
209	Biotechnologies to tackle the challenge of neoantigen identification. Current Opinion in Biotechnology, 2020, 65, 52-59.	6.6	25
210	Two-Dimensional Label-Free Affinity Analysis of Tumor-Specific CD8 T Cells with a Biomimetic Plasmonic Sensor. ACS Sensors, 2018, 3, 2286-2295.	7.8	24
211	Bone marrow-derived cells are implicated as a source of lymphatic endothelial progenitors in human breast cancer. OncoImmunology, 2014, 3, e29080.	4.6	23
212	Follicular Atresia and Luteolysis Evidence of a Role for Nâ€Cadherin. Annals of the New York Academy of Sciences, 2000, 900, 46-55.	3.8	22
213	Macrophage-Colony Stimulating Factor (M-CSF) Regulates the Expression of Fibronectin and Its Î±5 Integrin Receptor in Human Trophoblasts*. Endocrinology, 1998, 139, 2190-2193.	2.8	21
214	Tissue-based immune monitoring II. Cancer Biology and Therapy, 2011, 12, 367-377.	3.4	21
215	Targeting Cytokines: Production and Characterization of Anti-TNF-Î± scFvs by Phage Display Technology. Current Pharmaceutical Design, 2013, 19, 2839-2847.	1.9	21
216	Direct vaccination with tumor cells killed with ICP4-deficient HSVd120 elicits effective antitumor immunity. Cancer Biology and Therapy, 2006, 5, 867-874.	3.4	20

#	Article	IF	Citations
217	Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model. Cancer Biology and Therapy, 2014, 15, 443-451.	3.4	20
218	Overexpression of *GPC6* and *TMEM132D* in Early Stage Ovarian Cancer Correlates with CD8+ T-Lymphocyte Infiltration and Increased Patient Survival. BioMed Research International, 2015, 2015, 1-9.	1.9	20
219	Cell therapies in ovarian cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110083.	3.2	20
220	Vascular Leukocytes: a Population with Angiogenic and Immunossuppressive Properties Highly Represented in Ovarian Cancer. , 2007, 590, 185-193.		20
221	Luteogenic Hormones Act through a Vascular Endothelial Growth Factor-Dependent Mechanism to Up-Regulate $\alpha 5\beta 1$ and $\alpha v\beta 3$ Integrins, Promoting the Migration and Survival of Human Luteinized Granulosa Cells. American Journal of Pathology, 2007, 170, 1561-1572.	3.8	19
222	Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer. Journal of Translational Medicine, 2008, 6, 2.	4.4	19
223	RNA interference, A potential strategy for isoform-specific phosphatidylinositol 3-kinase targeted therapy in ovarian cancer. Cancer Biology and Therapy, 2004, 3, 1283-1289.	3.4	18
224	Know thy enemy. OncoImmunology, 2012, 1, 575-577.	4.6	18
225	Angiogenic Activity of Breast Cancer Patients' Monocytes Reverted by Combined Use of Systems Modeling and Experimental Approaches. PLoS Computational Biology, 2015, 11, e1004050.	3.2	18
226	Targeting Programmed Cell Death 1 in Ovarian Cancer. Journal of Clinical Oncology, 2015, 33, 3987-3989.	1.6	18
227	Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope. Nature Communications, 2021, 12, 6423.	12.8	18
228	Oncolytic therapy using a mutant type-1 herpes simplex virus and the role of the immune system. Annals of Thoracic Surgery, 1999, 68, 1756-1760.	1.3	17
229	High-throughput monitoring of human tumor-specific T-cell responses with large peptide pools. OncoImmunology, 2015, 4, e1029702.	4.6	17
230	Internal radiation dosimetry of a 152Tb-labeled antibody in tumor-bearing mice. EJNMMI Research, 2019, 9, 53.	2.5	17
231	Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes. , 2020, 8, e000875.		16
232	VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding. , 2021, 9, e002151.		16
233	Overexpression of SMARCE1 is associated with CD8+ T-cell infiltration in early stage ovarian cancer. International Journal of Biochemistry and Cell Biology, 2014, 53, 389-398.	2.8	15
234	Integrating SpyCatcher/SpyTag covalent fusion technology into phage display workflows for rapid antibody discovery. Scientific Reports, 2019, 9, 12815.	3.3	15

#	Article	IF	Citations
235	High-throughput Screening of Human Tumor Antigenâ€"specific CD4 T Cells, Including Neoantigen-reactive T Cells. Clinical Cancer Research, 2019, 25, 4320-4331.	7.0	15
236	miR-155 Overexpression in OT-1 CD8+ T Cells Improves Anti-Tumor Activity against Low-Affinity Tumor Antigen. Molecular Therapy - Oncolytics, 2020, 16, 111-123.	4.4	15
237	Preclinical Evaluation and Dosimetry of [111In]CHX-DTPA-scFv78-Fc Targeting Endosialin/Tumor Endothelial Marker 1 (TEM1). Molecular Imaging and Biology, 2020, 22, 979-991.	2.6	15
238	The fibronectin receptor Î±5 integrin subunit is upregulated by cell-cell adhesion via a cyclic AMP-dependent mechanism: Implications for human trophoblast migration. American Journal of Obstetrics and Gynecology, 2005, 192, 1240-1253.	1.3	14
239	Varying Coefficient Model with Unknown Withinâ€Subject Covariance for Analysis of Tumor Growth Curves. Biometrics, 2008, 64, 1023-1031.	1.4	14
240	Tumor vascular biomarkers: New opportunities for cancer diagnostics1. Cancer Biomarkers, 2011, 8, 253-271.	1.7	14
241	Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer. Oncotarget, 2014, 5, 6994-7012.	1.8	14
242	High versus low dose irradiation for tumor immune reprogramming. Current Opinion in Biotechnology, 2020, 65, 268-283.	6.6	13
243	Cancer and HIV-1 Infection: Patterns of Chronic Antigen Exposure. Frontiers in Immunology, 2020, 11, 1350.	4.8	13
244	Prophylactic oophorectomy. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2002, 16, 597-609.	2.8	12
245	Neoadjuvant immune-checkpoint blockade in resectable colon cancer. Nature Medicine, 2020, 26, 473-474.	30.7	12
246	Imaging angiogenesis in atherosclerosis in large arteries with 68Ga-NODAGA-RGD PET/CT: relationship with clinical atherosclerotic cardiovascular disease. EJNMMI Research, 2021, 11, 71.	2.5	12
247	CEA-targeted engineered IL2: Clinical confirmation of tumor targeting and evidence of intra-tumoral immune activation.. Journal of Clinical Oncology, 2015, 33, 3016-3016.	1.6	12
248	Intraperitoneal Oncolytic and Tumor Vaccination Therapy with Replication-Competent Recombinant Virus: The Herpes Paradigm. Current Gene Therapy, 2003, 3, 113-125.	2.0	12
249	Role of Vascular Leukocytes in Ovarian Cancer Neovascularization. , 2008, 622, 273-280.		11
250	Hierarchical Normalized Cuts: Unsupervised Segmentation of Vascular Biomarkers from Ovarian Cancer Tissue Microarrays. Lecture Notes in Computer Science, 2009, 12, 230-238.	1.3	11
251	Progestins Modulate the Action of Estrogen on Gonadotropin-Releasing Hormone, Luteinizing Hormone and Prolactin in the Rat. Gynecologic and Obstetric Investigation, 1990, 29, 197-202.	1.6	10
252	Tissue-based immune monitoring I. Cancer Biology and Therapy, 2011, 12, 357-366.	3.4	10

#	Article	IF	Citations
253	TIE2-expressing monocytes: A novel cellular biomarker for hepatocellular carcinoma?. Hepatology, 2013, 57, 1294-1296.	7.3	10
254	Deep Response to Anti-PD-1 Therapy of Metastatic Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumor With <i>CD274/PD-L1</i> Amplification. JCO Precision Oncology, 2019, 3, 1-6.	3.0	10
255	Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: A Biomarker for Use Beyond Prognosis?. Journal of Clinical Oncology, 2015, 33, 1297-1298.	1.6	9
256	Tumor Landscapes: Î²-Catenin Drives Immune Desertification. Clinical Cancer Research, 2019, 25, 2943-2945.	7.0	9
257	Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment. Cytotherapy, 2020, 22, 780-791.	0.7	9
258	Biogenesis of HLA Ligand Presentation in Immune Cells Upon Activation Reveals Changes in Peptide Length Preference. Frontiers in Immunology, 2020, 11, 1981.	4.8	9
259	Azole-Based Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 2205-2227.	6.4	9
260	Soluble trivalent engagers redirect cytolytic TÂcell activity toward tumor endothelial marker 1. Cell Reports Medicine, 2021, 2, 100362.	6.5	9
261	Replenish the source within. OncoImmunology, 2013, 2, e25912.	4.6	8
262	Analysis of Secondary Structure Biases in Naturally Presented HLA-I Ligands. Frontiers in Immunology, 2019, 10, 2731.	4.8	8
263	Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab. Clinical and Translational Radiation Oncology, 2021, 27, 85-88.	1.7	8
264	Unsupervised Analysis of Flow Cytometry Data in a Clinical Setting Captures Cell Diversity and Allows Population Discovery. Frontiers in Immunology, 2021, 12, 633910.	4.8	8
265	Impact of DOTA Conjugation on Pharmacokinetics and Immunoreactivity of [177Lu]Lu-1C1m-Fc, an Anti TEM-1 Fusion Protein Antibody in a TEM-1 Positive Tumor Mouse Model. Pharmaceutics, 2021, 13, 96.	4.5	8
266	Low-dose irradiation for reversing immunotherapy resistance: how to translate?. , 2022, 10, e004939.		8
267	Potential Roles for the Low Density Lipoprotein Receptor Family of Proteins in Implantation and Placentation. Annals of the New York Academy of Sciences, 1994, 734, 91-102.	3.8	7
268	Biological Therapy with Oncolytic Herpesvirus. , 2008, 622, 221-233.		7
269	Combine and Conquer: Double CTLA-4 and PD-1 Blockade Combined with Whole Tumor Antigen Vaccine Cooperate to Eradicate Tumors. Cancer Research, 2016, 76, 6765-6767.	0.9	7
270	CD8 Binding of MHC-Peptide Complexes in cis or trans Regulates CD8+ T-cell Responses. Journal of Molecular Biology, 2019, 431, 4941-4958.	4.2	7

#	Article	IF	Citations
271	Multielemental Analysis of Low-Volume Samples Reveals Cancer-Specific Profile in Serum and Sorted Immune Cells. Analytical Chemistry, 2020, 92, 8750-8758.	6.5	7
272	EORTC-ETOP randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with early stage non-small cell lung cancer (NSCLC) after resection and standard adjuvant chemotherapy: PEARLS (NCT02504372).. Journal of Clinical Oncology, 2016, 34, TPS8571-TPS8571.	1.6	7
273	A roadmap for driving CAR TÂcells toward the oncogenic immunopeptidome. Cancer Cell, 2022, 40, 20-22.	16.8	7
274	Early ovarian cancer. Current Treatment Options in Oncology, 2000, 1, 129-137.	3.0	6
275	Microfluidic device performing on flow study of serial cellâ€"cell interactions of two cell populations. RSC Advances, 2019, 9, 41066-41073.	3.6	6
276	Immune Prognostic Factors in Ovarian Cancer: Lessons from Translational Research. Disease Markers, 2007, 23, 445-452.	1.3	5
277	Current Opinion and Knowledge on Peritoneal Carcinomatosis: A Survey among a Swiss Oncology Network. Chemotherapy, 2018, 63, 143-147.	1.6	5
278	Microfluidic Device for Droplet Pairing by Combining Droplet Railing and Floating Trap Arrays. Micromachines, 2021, 12, 1076.	2.9	5
279	T regulatory cell depletion can boost DC-based vaccines. Cancer Biology and Therapy, 2005, 4, 628-630.	3.4	4
280	Expression profile of microRNA in epithelial cancer: diagnosis, classification and prediction. Expert Opinion on Medical Diagnostics, 2009, 3, 25-36.	1.6	4
281	Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy. OncoImmunology, 2016, 5, e1062210.	4.6	4
282	Going Beyond the Sequences: TCR Binding Patterns at the Service of Cancer Detection. Cancer Research, 2019, 79, 1299-1301.	0.9	4
283	Measurement of Mitochondrial Mass and Membrane Potential in Hematopoietic Stem Cells and T-cells by Flow Cytometry. Journal of Visualized Experiments, 2019, , .	0.3	4
284	Mineral and Amino Acid Profiling of Different Hematopoietic Populations from the Mouse Bone Marrow. International Journal of Molecular Sciences, 2020, 21, 6444.	4.1	4
285	A phase I, dose escalation trial to assess the safety and biological activity of recombinant human interleukin-18 (SB-485232) in combination with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer.. Journal of Clinical Oncology, 2012, 30, 5065-5065.	1.6	4
286	Manipulating T regulatory cells in cancer immunotherapy. Expert Review of Dermatology, 2006, 1, 589-597.	0.3	3
287	High-throughput identification of human antigen-specific CD8+ and CD4+ T cells using soluble pMHC multimers. Methods in Enzymology, 2020, 631, 21-42.	1.0	3
288	Guillain-BarrÃ© syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes. , 2020, 8, e001155.		3

#	Article	IF	Citations
289	Biological evaluation of new TEM1 targeting recombinant antibodies for radioimmunotherapy: In vitro, in vivo and in silico studies. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 158, 233-244.	4.3	3
290	Long-lasting, irreversible and late-onset immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs): A real-world data analysis.. Journal of Clinical Oncology, 2020, 38, e15095-e15095.	1.6	3
291	Deciphering the landscape of phosphorylated HLA-II ligands. IScience, 2022, 25, 104215.	4.1	3
292	Report on the ISBTC Mini-symposium on Biologic Effects of Targeted Therapeutics. Journal of Immunotherapy, 2007, 30, 577-590.	2.4	2
293	Monocytes TIE(2)d up in murky business. Blood, 2007, 109, 5076-5076.	1.4	2
294	Successful engineering cancer immunotherapy. European Journal of Immunology, 2014, 44, 318-320.	2.9	2
295	MicroRNAs in Epithelial Ovarian Cancer. , 2011, , 309-342.		2
296	A cell-based phenotypic library selection and screening approach for the de novo discovery of novel functional chimeric antigen receptors. Scientific Reports, 2022, 12, 1136.	3.3	2
297	Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC. Lancet Oncology, The, 2022, 23, e157.	10.7	2
298	Dendritic Cells: From Inducers of Specific T-Cell Responses to Promoters of Angiogenesis. , 2009, , 231-241.		1
299	The Microenvironment of Ovarian Cancer: Lessons on Immune Mediated Tumor Rejection or Tolerance. , 2011, , 211-228.		1
300	Predictive biomarkers for response to nivolumab in head and neck squamous cell carcinoma (HNSCC) (NCT#03652142).. Journal of Clinical Oncology, 2019, 37, 6060-6060.	1.6	1
301	High-Throughput Single-Cell TCRâ€"pMHC Dissociation Rate Measurements Performed by an Autonomous Microfluidic Cellular Processing Unit. ACS Sensors, 2022, 7, 159-165.	7.8	1
302	TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodulation and eradication of ovarian cancer.. BioImpacts, 2022, 12, 65-86.	1.5	1
303	Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 1773-1811.	5.2	1
304	Prophylactic oophorectomy for ovarian cancer. Reviews in Gynaecological and Perinatal Practice, 2006, 6, 12-19.	0.3	0
305	Immuno-imaging and -therapy in ovarian cancer and sarcoma with de novo single-chain fv-fc fusion protein targeting TEM1/CD248. , 2014, 2, .		0
306	In-depth immune and molecular profiling of melanoma patients receiving adoptive T-cell therapy reveals biomarkers of efficacy in ATATIL study.. Journal of Clinical Oncology, 2021, 39, 2533-2533.	1.6	0

#	Article	IF	Citations
307	BRCA1 and BRCA2 Mutations in Ovarian Carcinoma. , 2003, , 201-208.		0
308	Cancer Gene Therapy: Targeted Genomedicines. , 0, , .		0
309	What Is the Future of Immunotherapy in Ovarian Cancer?. , 2014, , 323-337.		0
310	Angiogenesis and Immune Suppression in Cancer. , 2014, , 213-238.		0
311	Autologous oxidized whole-tumor antigen vaccine in combination with angiogenesis blockade to elicit antitumor immune response in ovarian cancer.. Journal of Clinical Oncology, 2015, 33, 5519-5519.	1.6	0